In a 40-year-old woman with a 3.4 cm cystic pancreatic mass identified on CT, should I order a contrast‑enhanced abdominal MRI or a dedicated contrast‑enhanced MRI of the pancreas?

Order MRI Abdomen with MRCP (with contrast)

For a 3.4 cm cystic pancreatic mass in a 40-year-old woman, you should order a contrast-enhanced MRI of the abdomen with MRCP—this is the same as ordering "MRI abdomen with contrast" when you specify that MRCP sequences should be included. There is no practical distinction between "MRI of abdomen" and "MRI of pancreas" in radiology ordering systems; the key is ensuring the protocol includes both contrast-enhanced sequences and MRCP 1.

Why MRI with MRCP is the Procedure of Choice

The 2020 ACR Appropriateness Criteria explicitly state that contrast-enhanced MRI with MRCP is considered the procedure of choice for evaluating pancreatic cysts >2.5 cm 1. Your patient's 3.4 cm cyst falls into the category of "Variant 2: Incidentally detected pancreatic cyst greater than 2.5 cm in size" from these guidelines.

Superior Diagnostic Performance

MRI with MRCP significantly outperforms CT for this indication:

• Sensitivity and specificity for distinguishing IPMN from other cystic lesions: 96.8% and 90.8% for MRI versus only 80.6% and 86.4% for CT 1
• Sensitivity for detecting ductal communication approaches 100% with thin-slice 3D MRCP sequences 1
• Sensitivity for detecting internal septations: 91% for MRI versus 73.9-93.6% for CT 1
• Diagnostic accuracy for distinguishing malignant from benign lesions: 73.2-91% 1

Why This Matters for Your Patient

At 3.4 cm, this cyst meets the definition of a "worrisome feature" (cysts ≥3 cm are associated with a 3-times greater risk of malignancy) 1. The superior soft-tissue resolution of MRI is critical because you need to:

1. Identify communication with the pancreatic duct (suggests IPMN vs other cyst types)
2. Detect mural nodules, thick septations, or solid components (high-risk features requiring EUS-FNA or surgery)
3. Assess main pancreatic duct caliber (dilation >7 mm is worrisome; ≥10 mm is high-risk)
4. Establish a baseline for future surveillance if no immediate intervention is needed

Practical Ordering Considerations

When ordering, specify:

• "MRI abdomen with and without IV contrast with MRCP"
• This automatically includes dedicated pancreatic imaging sequences
• The MRCP component (non-contrast T2-weighted sequences) evaluates ductal anatomy
• The contrast-enhanced sequences detect enhancing nodules and assess vascularity

Common Pitfall to Avoid

Do not order CT instead of MRI unless the patient has an absolute contraindication to MRI (e.g., incompatible pacemaker, severe claustrophobia unresponsive to anxiolytics, metallic foreign body). The European guidelines similarly recommend MRI as the preferred surveillance method, noting that repeated CT exposure increases malignancy risk in patients who may require lifelong follow-up 2.

What Happens After MRI

Based on MRI findings, management will follow this algorithm 1:

• No worrisome features: Surveillance imaging
• Worrisome features present (your patient already has one—size ≥3 cm): Consider EUS-FNA for cyst fluid analysis and cytology
• High-risk stigmata (enhancing solid component, obstructive jaundice, main duct ≥10 mm): Surgical referral

The MRI will determine which pathway is appropriate and whether EUS-FNA should be the next step 1.